MDL | MFCD00084820 |
---|---|
Molecular Weight | 78.10 |
Molecular Formula | H2O3Si |
SMILES | O[Si](O)=O.[0.75 Mg] |
NCT Number | Sponsor | Condition | Start Date | Phase |
---|---|---|---|---|
NCT00767962 | Assistance Publique Hopitaux De Marseille |
Pneumothorax
|
February 2009 | Not Applicable |
NCT04806373 | Memorial Healthcare System|Genentech, Inc. |
Pleural Effusion
|
June 15, 2021 | Phase 4 |
NCT04130451 | Dow University of Health Sciences |
Secondary Pneumothorax
|
October 25, 2019 | Phase 1|Phase 2 |
NCT02825095 | Rambam Health Care Campus |
Pleural Effusion, Malignant|Lung Neoplasms
|
August 2016 | Early Phase 1 |
NCT02674243 | Chiang Mai University |
Malignant Pleural Effusion
|
November 2015 | Phase 3 |
NCT00789087 | University of Sao Paulo |
Recurrent Malignant Pleural Effusion.
|
January 2005 | Phase 4 |
NCT00430664 | Postgraduate Institute of Medical Education and Research |
Malignant Pleural Effusions|Recurrent Pleural Effusions|Primary Spontaneous Pneumothorax|Secondary Spontaneous Pneumothorax
|
January 2006 | Not Applicable |
NCT02288065 | KU Leuven |
Pleuritis
|
January 2014 | |
NCT02045121 | National University Hospital, Singapore |
Pleural Effusion, Malignant
|
January 2014 | Not Applicable |
NCT03973957 | The Cooper Health System |
Pleural Effusion|Pleural Diseases|Malignant Pleural Effusion
|
May 27, 2019 | Not Applicable |
NCT00530452 | CrystalGenomics, Inc.|Quintiles, Inc. |
Osteoarthritis, Knee|Osteoarthritis, Hip
|
October 2007 | Phase 2 |
NCT04792970 | Duke University |
Malignant Pleural Effusion
|
March 18, 2021 | Phase 4 |
NCT00042770 | Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI) |
Metastatic Cancer|Pulmonary Complications
|
May 2002 | Phase 3 |
NCT01973985 | University of Oxford |
Pleural Effusion
|
August 1, 2014 | |
NCT03319186 | NHS Greater Glasgow and Clyde|Rocket Medical plc |
Pleural Effusion, Malignant
|
August 28, 2017 | Not Applicable |
NCT00002872 | Eastern Cooperative Oncology Group|National Cancer Institute (NCI)|North Central Cancer Treatment Group |
Metastatic Cancer
|
November 1996 | Phase 3 |
NCT02283736 | Jorge Gamonal|University of Chile |
-Chronic Periodontitis
|
June 2014 | Phase 2 |
NCT02517749 | Guy´s and St Thomas´ NHS Foundation Trust|Becton, Dickinson and Company |
Pleural Effusion, Malignant
|
August 2015 | Not Applicable |
NCT00821860 | Papworth Hospital NHS Foundation Trust |
Malignant Mesothelioma|Metastatic Cancer
|
September 2003 | Phase 3 |
NCT01409551 | Theagenio Cancer Hospital |
Safety of Intervention|Efficacy of Intervention|Cost Effectiveness
|
August 2011 | Not Applicable |
NCT02839408 | University of Chile |
Chronic Periodontitis
|
June 2015 | Phase 2 |
NCT01469728 | University of Rome Tor Vergata |
Pleural Effusion
|
November 2007 | Phase 2 |
NCT00002622 | Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI)|Eastern Cooperative Oncology Group|Radiation Therapy Oncology Group|North Central Cancer Treatment Group |
Metastatic Cancer
|
December 1994 | Phase 3 |
Solid
Room temperature in continental US; may vary elsewhere.
Powder | -20°C | 3 years |
---|---|---|
4°C | 2 years | |
In solvent | -80°C | 6 months |
-20°C | 1 month |
H 2 O : < 0.1 mg/mL (ultrasonic;warming;heat to 60°C) (insoluble)
DMSO : < 1 mg/mL (ultrasonic;warming;heat to 60°C) (insoluble or slightly soluble)